ucb0022
Small moleculeexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Apr 29, 2021 (NCT04867642)
Timeline
Indications
Mechanism of action
- Dopamine D1 receptorMODULATOR
DRD1 modulator
Chemistry & pharmacology
Loading structure…
SMILES
C[C@H]1c2cccc(C(C)(C)O)c2C[C@H](CO)N1C(=O)Cc1c(Cl)ccc2c1c(Cl)nn2C- Mol. weight
- 476.4 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL6068015 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07220551 | Phase 1 | Oct 23, 2025 | UCB |
| NCT06970301 | Phase 1 | Apr 28, 2025 | UCB |
| NCT06055985 | Phase 2 | Nov 17, 2023 | UCB |
| NCT04867642 | Phase 1 | Apr 29, 2021 | UCB |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| UCB | For profit | 4 | 4 | 2 | 2021 |
1 organizations
Page 1 / 1